Something strange happened. On Monday, 18 May, Moderna, a biotech company based in the US, held a press conference in which it released positive preliminary data on its ongoing vaccine program for covid-19.
Its stock price reached stratospheric heights. The following day, perhaps suffering from the hangover of the initial euphoria, with the sobering realization that there is still a long way to go before any vaccine can be deemed successful, Moderna’s share price started to slide.
We really need a vaccine. SARS-CoV-2, the pandemic coronavirus that causes covid-19 has infected over five million people globally.
Ravaging much of Asia, Europe, and North America, it is now intensifying in South America and Africa. Because it is a new virus